RxDoctor Payments Data

Andrew Cho, MD

Ophthalmology · Los Angeles, CANPI 1225072481

Payments from drug & device makers

$23,925in general payments, 2019–2025

Across 666 payments — averaging $35.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$5K
  • AbbVie$4K
  • Kala Pharmaceuticals, Inc.$1K
  • Alcon$1K
  • Aerie Pharmaceuticals, Inc.$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • plus $10K from 32 others

What the payments were for

  • Consulting fees$1,3006%
  • Speaking & faculty fees$6003%
  • Food & beverage$18,01788%
  • Gifts$370%
  • Other$5123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,925 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$2,105,608
Medicare patients
954
Services billed
11,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine3,485$3,029,391
Cyclosporine1,745$822,101
VascepaIcosapent Ethyl804$369,325
MieboPerfluorohexyloctane/Pf262$268,605
RhopressaNetarsudil Mesylate423$182,898
CequaCyclosporine229$171,475
VyzultaLatanoprostene Bunod368$142,297
Timoptic OcudoseTimolol Maleate/Pf171$114,719
Alphagan PBrimonidine Tartrate313$89,015
XiidraLifitegrast81$66,950
LumiganBimatoprost178$66,937
CombiganBrimonidine Tartrate/Timolol172$54,251
Icosapent Ethyl171$43,861
RocklatanNetarsudil Mesylat/Latanoprost87$38,711
ZioptanTafluprost/Pf104$38,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan, Combigan$3,788$3,239,5944,148 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta, Xiidra$1,093$477,852711 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$1,351$221,609510 claims
Sun Pharmaceutical Industries Inc.Cequa$1,264$171,475229 claims
Akorn, Inc.Zioptan$230$38,329104 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$1,040$36,288107 claims
AlconAzopt, Simbrinza$1,414$32,125100 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$749$26,59514 claims
Eyevance Pharmaceuticals LLCTobradex St, Zerviate$710$19,37173 claims
Thea Pharma Inc.Iyuzeh$254$14,58929 claims
Oyster Point Pharma, Inc.Tyrvaya$191$14,37522 claims
Kala Pharmaceuticals, Inc.Eysuvis$1,430$6,82914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →